Question 1

What are the indications and effects of Hutika Tablets 60 mg (Ticagrelor)?

Accepted Answer

This medication helps reduce the incidence of thrombotic cardiovascular events when used in conjunction with aspirin. It is particularly useful for patients with acute coronary syndrome or patients at risk of thrombotic cardiovascular events who have experienced a myocardial infarction more than one year ago. Additionally, it can lower the risk of myocardial infarction and stroke in patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease. In cases of acute ischemic stroke or high-risk transient ischemic attacks (TIA), it reduces the incidence of stroke when used in combination with aspirin. Thus, this medication is effectively used for the prevention of thrombotic events in various cardiovascular disease patients.

Question 2

What are the dosage and administration instructions for Hutika Tablets 60 mg (Ticagrelor)?

Accepted Answer

Do not use this product concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel).
Acute coronary syndrome: Administer a 180mg loading dose, followed by 90mg per dose twice daily. Treatment is recommended for 12 months unless discontinuation of this product is clinically necessary. Patients taking this product should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated.
In patients with acute coronary syndrome who have an increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this product (discontinuation of aspirin) may be considered after 3 months of concomitant treatment with this product and aspirin.
Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg per dose twice daily. Patients taking this product should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated.
Patients who took 90mg of this product or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this product.
Treatment with this product may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel).
The safety and efficacy of this product were evaluated at 3 years of follow-up.
Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg per dose twice daily. Patients taking this product should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated.
Refer to the dosage and administration for patients with acute coronary syndrome.
Data on the safety and efficacy of this product for treatment lasting more than 3 years are limited.
Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer a 180mg loading dose, followed by 90mg per dose twice daily for 30 days. Patients taking this product should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack.
This product is administered orally and may be taken with or without food.
For patients who have difficulty swallowing tablets, crush this product into a fine powder, disperse it in half a glass of water, and drink the mixture immediately. Rinse the glass used with half a glass of water and drink again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration.
When switching from another antiplatelet agent to this product, start this product 24 hours after the last dose of the previous medication.
If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time.
No dose adjustment is necessary in patients with renal impairment.
No dose adjustment is necessary in patients with mild hepatic impairment. This product has not been studied in patients with severe hepatic impairment, and there is limited treatment experience in patients with moderate hepatic impairment.

Answer

The safety and efficacy of this product in pediatric patients under 18 years of age have not been established.

Question 3

What are the side effects of Hutika Tablets 60 mg (Ticagrelor)?

Accepted Answer

Hemorrhage, dyspnea, hyperuricemia, gout, confusion, dizziness, syncope, headache, intracranial hemorrhage, ocular hemorrhage, vertigo, ear hemorrhage, hypotension, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, subcutaneous or skin hemorrhage, rash, pruritus, muscle hemorrhage, urinary tract hemorrhage, genitourinary tract hemorrhage, increased serum creatinine, post-procedural hemorrhage, traumatic hemorrhage, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, Cheyne-Stokes respiration, central sleep apnea, chest pain, cough, pulmonary hemorrhage, pharyngitis, upper respiratory tract infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, weakness, anaphylactic shock, epistaxis, hemoptysis, hematoma, cerebral hemorrhage, spinal stenosis, dementia, migraine, paralysis, gait disturbance, rectal hemorrhage, anal hemorrhage, appendicitis, tendinopathy, bursitis, rhabdomyolysis, acute renal failure, aneurysm, heart failure, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stone, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina pectoris, coronary artery thrombosis, myocardial ischemia, anemia, vestibular disorder, malignant male genital neoplasm, chemical poisoning, post-procedural hematoma, laceration, road traffic accident, trauma, sinusitis, bronchiectasis, sleep apnea, pulmonary congestion, oral edema, influenza-like syndrome, tuberculosis infection, hyperthermia, unspecified hernia, shortness of breath, generalized edema, thrombosis, deep vein thrombosis, cardiac thrombus, coagulopathy, thrombocytosis, speech disorder, cerebral hypoxia, scalp tenderness, peripheral neuropathy, neck stiffness, voice disorder, seizure, neuropathy, neuralgia, movement disorder, tremor, lower limb paralysis, coma, sensory loss, oral pain, gastroenteritis, belching, irritable bowel syndrome, stomatitis, ulcerative stomatitis, benign gastrointestinal neoplasm, dental disease, tongue disease, tendinitis, arthrosis, cartilage calcification, spinal osteoarthritis, arthritis, contact dermatitis, fungal dermatitis, skin disease, erythematous rash, hyperkeratosis, acute urticaria, onychomycosis, hair loss, scleroderma, soft fibromas of the skin, increased sweating, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, lipodystrophy, dehydration, hepatitis, cholelithiasis, gallbladder disease, increased alkaline phosphatase, fatty liver, drowsiness, neurosis, depression, snoring, hallucination, orthostatic hypotension, aggravation of hypertension, cyanosis, atrial arrhythmia, complete atrioventricular block, urinary incontinence, nocturia, exacerbation of chronic renal failure, cystitis, urinary abnormalities, renal cyst, benign renal neoplasm, urinary retention, azotemia, conjunctivitis, diabetic retinopathy, cataract, cardiomyopathy, cardiac compression, pericardial effusion, abscess, oral candidiasis, herpes zoster, bacterial infection, esophageal candidiasis, decreased blood iron, tinnitus, ear pain, lymphadenopathy, eosinophilia, leukocytosis, sexual dysfunction, benign prostatic hyperplasia, ovarian cyst, amenorrhea, vaginitis, loss of taste, altered smell, increased TSH, hypothyroidism, injection site reaction, injection site pain, insomnia, anxiety, memory impairment, erectile dysfunction, agitation, palpitations, bradycardia, atrial fibrillation, conjunctival congestion, eye pain, visual disturbances

Question 4

What precautions should be taken when using Hutika Tablets 60 mg (Ticagrelor)?

Accepted Answer

This medication is designed to prevent blood clotting; however, it may increase the risk of bleeding, and should not be used in patients with bleeding disorders or a history of intracranial hemorrhage. If surgery is planned, it should be discontinued at least 5 days before the procedure, and caution is advised due to potential bleeding during surgery. If bleeding symptoms occur, notify healthcare professionals immediately, and treatment for the bleeding should be initiated without discontinuing the medication if possible. Patients with hypersensitivity to this medication, severe liver dysfunction, or who are taking strong CYP3A4 inhibitors should not use this medication. Caution should be exercised if administered to patients at high risk of bleeding or those taking other medications that may cause bleeding, especially when used concurrently with warfarin. Patients at risk of bradycardia or decreased heart rate, as well as those with asthma or chronic obstructive pulmonary disease, should also use caution when taking this medication. Respiratory distress may occur, and discontinuation of treatment should be considered in such cases. Women who are pregnant or breastfeeding should consult with a specialist regarding the potential effects on the fetus or newborn. This medication is not recommended for children under 18, as safety and efficacy have not been established. In case of overdose, the risk of bleeding is increased, and since there is no specific antidote, appropriate treatment should be sought immediately. It is recommended to use low-dose aspirin (75-150 mg) in conjunction with this medication, and high-dose aspirin is not recommended. Additionally, this medication may interact with various other drugs, so patients should inform healthcare providers about any other medications being taken. Caution is advised as dizziness or confusion symptoms may occur when driving or operating machinery. The most common side effects are bleeding and respiratory distress; patients with hyperuricemia or gout should also proceed with caution. Regular monitoring of kidney function and bleeding symptoms during treatment is important.

Hutika Tablets 60 mg (Ticagrelor)

Summary

Ingredients

Efficacy & effects

How to take

Adult dose

Child dose

Precautions

Side effects

Storage

Appearance and packaging

Appearance

Package unit

Same-ingredient medicines

Hutika Tablets 60 mg (Ticagrelor)

Brilinta Tablets 90 mg (Ticagrelor)

Brilinta Tablet 60mg (Ticagrelor)

Innoentica Clopidogrel Tablets 60 Milligrams

Innoentica Clopidogrel Tablets 90 mg

Anguk Ticagrelor Tablets 60 mg

Anguk Ticagrelor Tablets 90 mg

Brilique Tablet 90 mg (Ticagrelor)

Questions about this medicine

Related searches

Search tags

Suggested searches